| Prasugrel versus clopidogrel in patients with acute coronary syndromes SD Wiviott, E Braunwald, CH McCabe, G Montalescot, W Ruzyllo, ... New England Journal of Medicine 357 (20), 2001-2015, 2007 | 8164 | 2007 |
| Edoxaban versus warfarin in patients with atrial fibrillation RP Giugliano, CT Ruff, E Braunwald, SA Murphy, SD Wiviott, JL Halperin, ... New England Journal of Medicine 369 (22), 2093-2104, 2013 | 5830 | 2013 |
| Dapagliflozin and cardiovascular outcomes in type 2 diabetes SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... New England Journal of Medicine 380 (4), 347-357, 2019 | 5721 | 2019 |
| Evolocumab and clinical outcomes in patients with cardiovascular disease MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SD Wiviott, ... New England journal of medicine 376 (18), 1713-1722, 2017 | 5585 | 2017 |
| Ezetimibe added to statin therapy after acute coronary syndromes CP Cannon, MA Blazing, RP Giugliano, A McCagg, JA White, P Theroux, ... New England Journal of Medicine 372 (25), 2387-2397, 2015 | 4793 | 2015 |
| Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium R Mehran, SV Rao, DL Bhatt, CM Gibson, A Caixeta, J Eikelboom, S Kaul, ... Circulation 123 (23), 2736-2747, 2011 | 4227 | 2011 |
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus BM Scirica, DL Bhatt, E Braunwald, PG Steg, J Davidson, B Hirshberg, ... New England Journal of Medicine 369 (14), 1317-1326, 2013 | 4176 | 2013 |
| Cytochrome p-450 polymorphisms and response to clopidogrel JL Mega, SL Close, SD Wiviott, L Shen, RD Hockett, JT Brandt, JR Walker, ... New England journal of medicine 360 (4), 354-362, 2009 | 3116 | 2009 |
| SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome … TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ... The Lancet 393 (10166), 31-39, 2019 | 2598 | 2019 |
| Rivaroxaban in patients with a recent acute coronary syndrome JL Mega, E Braunwald, SD Wiviott, JP Bassand, DL Bhatt, C Bode, ... New England Journal of Medicine 366 (1), 9-19, 2012 | 2441 | 2012 |
| Long-term use of ticagrelor in patients with prior myocardial infarction MP Bonaca, DL Bhatt, M Cohen, PG Steg, RF Storey, EC Jensen, ... New England Journal of Medicine 372 (19), 1791-1800, 2015 | 2141 | 2015 |
| Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents L Mauri, DJ Kereiakes, RW Yeh, P Driscoll-Shempp, DE Cutlip, PG Steg, ... New England Journal of Medicine 371 (23), 2155-2166, 2014 | 2096 | 2014 |
| Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel … SD Wiviott, D Trenk, AL Frelinger, M O’Donoghue, FJ Neumann, ... Circulation 116 (25), 2923-2932, 2007 | 1967* | 2007 |
| Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JA de Lemos, MA Blazing, SD Wiviott, EF Lewis, KAA Fox, HD White, ... Jama 292 (11), 1307-1316, 2004 | 1905 | 2004 |
| Efficacy and safety of evolocumab in reducing lipids and cardiovascular events MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, DJ Blom, J Robinson, ... New England Journal of Medicine 372 (16), 1500-1509, 2015 | 1671 | 2015 |
| Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JL Mega, T Simon, JP Collet, JL Anderson, EM Antman, K Bliden, ... Jama 304 (16), 1821-1830, 2010 | 1393 | 2010 |
| Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised … G Montalescot, SD Wiviott, E Braunwald, SA Murphy, CM Gibson, ... The Lancet 373 (9665), 723-731, 2009 | 1386 | 2009 |
| Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis MG Silverman, BA Ference, K Im, SD Wiviott, RP Giugliano, SM Grundy, ... Jama 316 (12), 1289-1297, 2016 | 1345 | 2016 |
| Vorapaxar in the secondary prevention of atherothrombotic events DA Morrow, E Braunwald, MP Bonaca, SF Ameriso, AJ Dalby, MP Fish, ... New England Journal of Medicine 366 (15), 1404-1413, 2012 | 1102 | 2012 |
| Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials ML O'Donoghue, E Braunwald, EM Antman, SA Murphy, ER Bates, ... The Lancet 374 (9694), 989-997, 2009 | 1035 | 2009 |
